GAITHERSBURG, Md., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has commenced dosing in a Phase 1 single ...

--Altimmune, Inc., a clinical-stage biopharmaceutical company, today announced a preclinical data presentation on ALT-801, its balanced and long-acting GLP-1/glucagon receptor dual agonist under ...

ALT-801 is a long-acting GLP-1/glucagon receptor dual agonist being developed for the treatment of non-alcoholic steatohepatitis, which is expected to affect ...

Pemvidutide is a novel, peptide-based glucagon-like peptide-1/glucagon dual receptor agonist. The Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the ...

ALT-801 is an investigational GLP-1 & glucagon dual receptor agonist currently being studied for obesity and NASH indications. Source: Altimmune Q2 2021 presentation - ALT-801 mechanism of action ...

GAITHERSBURG, Md., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced a preclinical data presentation on ALT-801, its ...

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is ...

The company is leaning on Pemvidutide for obesity, NAFLD, and NASH. So far, the dual GLP-1/glucagon receptor agonist has produced impressive results in addressing metabolic dysfunction, which ...

Nonalcoholic steatohepatitis (NASH) ... The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known. Methods.

The company's lead candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, has shown promising results in clinical trials for obesity and metabolic dysfunction-associated steatohepatitis ...

Merck & Co. says its dual GLP-1/glucagon receptor co-agonist efinopegdutide beat out Novo Nordisk's Ozempic in the tricky indication of nonalcoholic fatty liver disease (NAFLD). While NAFLD may be ...